Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →
| Conto economico | TTM → 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entrate totali | $1.5B | $606M | $364M | $305M | $245M | $188M | $164M | $136M | $10M | $0M | $0M | $0M | $12M | $12M | $0M | $4M | $7M | $10M | $12M | $8M | $1M |
| Utile lordo | $1.3B | $482M | $278M | $240M | $190M | $144M | $125M | $112M | $7M | ($3M) | ($2M) | ($2M) | ($22M) | ($18M) | ($21M) | $4M | $7M | $10M | $12M | $7M | $0M |
| Margine lordo% | 84.2% | 79.4% | 76.4% | 78.5% | 77.5% | 76.6% | 75.8% | 82.3% | 75.4% | — | — | — | -191.6% | -157.8% | — | 100.0% | 100.0% | 100.0% | 100.0% | 92.3% | -50.3% |
| Risultato Operativo (EBIT) | — | ($1.2B) | ($878M) | ($710M) | ($457M) | ($375M) | ($265M) | ($235M) | ($307M) | ($189M) | ($173M) | ($117M) | ($87M) | ($55M) | ($42M) | ($62M) | ($8M) | ($9M) | ($14M) | ($20M) | ($54M) |
| Margine operativo % | — | -194.0% | -241.5% | -232.5% | -186.4% | -199.0% | -161.3% | -172.4% | -3124.9% | — | — | — | -759.7% | -478.4% | — | -1397.3% | -116.9% | -83.6% | -123.2% | -271.5% | -5486.7% |
| Reddito netto | ($605M) | ($1.3B) | ($914M) | ($750M) | ($482M) | ($435M) | ($294M) | ($254M) | ($324M) | ($193M) | ($176M) | ($118M) | ($79M) | ($56M) | ($41M) | ($60M) | ($6M) | $118M | ($16M) | ($20M) | ($56M) |
| Margine netto% | -39.8% | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | -178.9% | -186.4% | -3297.2% | — | — | — | -688.3% | -487.6% | — | -1350.8% | -93.0% | 1140.9% | -133.9% | -265.1% | -5664.9% |
| EBITDA | — | ($1.2B) | ($819M) | ($660M) | ($447M) | ($384M) | ($250M) | ($217M) | ($295M) | ($184M) | ($170M) | ($115M) | ($86M) | ($54M) | ($40M) | ($59M) | ($6M) | $120M | ($13M) | ($20M) | ($51M) |
| Utile per azione (EPS) | $-2.82 | $-5.98 | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 | $-4.22 | $-2.89 | $-2.85 | $-2.02 | $-1.84 | $-1.60 | $-1.56 | $-2.56 | $-0.49 | $9.30 | $-1.28 | $-1.74 | $-5.89 |
| Azioni in circolazione (M) | — | 214M | 164M | 140M | 123M | 112M | 98M | 85M | 77M | 67M | 62M | 59M | 43M | 35M | 27M | 23M | 13M | 13M | 12M | 11M | 10M |
Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.
Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di INSM. /companies/us/INSM
Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.
About TickerBase · Data methodology & sources · Privacy · Terms